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J Sex MedBackground: Cyproterone acetate (CA) is an antiandrogenic progestin commonly used in adult transwomen to
suppress endogenous androgens, often in combination with estrogens to induce feminization.
Aim: To assess the (side) effects and biochemical changes of CA alone and in combination with estrogens in
adolescent trans-girls.
Methods: This study was a retrospective analysis of clinical and biochemical data from 27 trans-girls who presented
at Tanner stage G4 and were treated with CA monotherapy for at least 6 months (mean ¼ 12 months) and then in
combination with incremental doses of estrogens (CA þ E; mean ¼ 16 months). Statistical analysis of data
included paired or unpaired Student t-test or Wilcoxon signed-ranks or Mann-Whitney U-test as appropriate.
Outcomes: Anthropometrics, reported beneﬁcial and side effects, safety parameters, and hormone levels.
Results: Physical changes included decrease of facial and non-facial hair growth. One third showed breast
development under CA (Tanner stages B2eB3), which increased to Tanner stages B3 and B4 in 66.7% and
9.5% respectively, during CA þ E. Reported side effects during CA and CA þ E were breast tenderness,
emotionality, fatigue, and ﬂushes. No relevant weight changes were observed. Main safety parameters showed the
following changes. Hemoglobin and hematocrit decreased and liver enzymes transiently and modestly increased
during CA. Triglycerides and cholesterol levels slightly decreased during CA but returned to baseline during
CA þ E; glucose metabolism was unaffected. Relevant hormonal changes included a decrease in gonadotropins
during CA þ E and in total and free testosterone levels throughout treatment. Prolactin levels increased during
CA and were restored during CA þ E.
Clinical Implications: CA produced modest feminizing effects in trans-girls and therefore might be a valuable
alternative in situations in which gonadotropin-releasing hormone analogues are not the treatment of choice and/
or are not reimbursed.
Strengths and Limitations: This is the ﬁrst study to report on the effects of CA in the treatment of trans-girls
and one of the few to report on the use of estrogens in this population. Limitations are the modest sample size
and the retrospective nature of this study.
Conclusion: Treatment with CA in late-pubertal trans-girls overall was safe and well tolerated and induced mild
clinical and biochemical feminizing changes. Rapid further feminization was observed with incremental doses of E.
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Gender dysphoria (GD) is deﬁned as an incongruence be-
tween the natal and the experienced or expressed gender, which
negatively affects different areas of functioning and/or entails
important distress.1 Worldwide, the number of adolescents
presenting with GD is increasing.2
In many cases, persistent GD is already present in childhood.
However, the condition will persist after the onset of puberty
only in a minority of children with GD.3 Therefore, it is rec-
ommended not to start medical therapy until the diagnosis of
persistent GD is conﬁrmed during early puberty (Tanner stages
2e3).4 Meanwhile, psychological guidance can be offered to the
child and should be continued in adolescence throughout the
transition period.5
The goal of medical treatment is to suppress the further
development of secondary sex characteristics, giving the adoles-
cent more time to explore his or her gender identity and to
decrease the extent of eventual later sex-reassignment surgery.6
The decision to initiate medical treatment is to be made by an
experienced multidisciplinary team, which in our center consists
of a child psychologist, a child psychiatrist, and a pediatric
endocrinologist.
In many centers, gonadotropin-releasing hormone analogues
(GnRHas) are preferred as ﬁrst-line therapy to suppress endog-
enous hormones. However, GnRHas are expensive and their
beneﬁcial effects are less clear in advanced pubertal stages,
because established secondary sexual characteristics do not regress
under GnRHas.7 Another disadvantage of GnRHas in trans-girls
is that, when started in early puberty, subsequent underdevel-
opment of the penis can compromise later penile inversion
vaginoplasty.8
We recently reported that the androgenic progestin lynestrenol
is a safe and valuable alternative for GnRHas in late-pubertal
trans-boys.9 In adult transwomen, experience has been gained
with antiandrogenic progestins such as cyproterone acetate (CA)
in combination with estrogens.10 However, data are lacking for
children and adolescents. CA effectively suppresses
gonadotropin-independent precocious puberty and was used to
suppress central precocious puberty before the advent of
GnRHas.11,12 Treatment with CA (Androcur, Bayer AG, Lev-
erkusen, Germany) is more than ﬁve times cheaper than treat-
ment with GnRHas, which in Belgium are not reimbursed for
the treatment of transgender persons, and can be administered
orally. The potent antiandrogenic effects result from its ability to
competitively inhibit androgen binding on the androgen recep-
tor, translocation of the androgen receptor to the nucleus, and
inhibition of androgen-mediated transcriptional activation.13 CA
decreases growth of body hair and to a lesser extent facial hair
and decreases sexual desire, which is often a cause of distress in
natal boys with GD.14,15 Because of these potent effects and the
high costs of GnRHas, CA is used in our center in adolescents
who already have established secondary sexual characteristics(Tanner stage  4) to alleviate distress before the addition of
estrogens. Increases of prolactin levels and stimulatory effects on
meningiomas and prolactinomas have been reported.16,17
According to the 2009 Endocrine Society clinical practice
guideline, puberty-suppressing therapy in transgender adolescents
can be associated with cross-sex hormones (CSHs) from at least
16 years of age.18 Strict adherence to this age criterion is some-
what controversial. Adolescent-speciﬁc data on the use of estro-
gens in trans-girls are virtually inexistent, and guidelines are
derived from studies in adults. Although estrogens alone can
decrease the production of androgens in transwomen, combina-
tion with CA has been reported to be more effective in decreasing
androgenic effects.19 17b-Estradiol (E) is the preferred estradiol,
because it has a lower thrombogenic proﬁle than ethinyl
estradiol.20e23 Based on limited evidence, estrogen-induced
breast development in transwomen has been reported to be
relatively modest. Possibly, breast development is more pro-
nounced in cases in which treatment is initiated at a younger age
and/or doses are increased stepwise.24 We report on the efﬁcacy
and safety of CA alone and then in combination with estrogens in
late-pubertal individuals who seek male-to-female transition.AIM
We report on the physical and hormonal changes and the
safety of treatment with CA as monotherapy and then in com-
bination with incremental E doses in transgender female ado-
lescents with GD.METHODS
Patients
All trans-girls who received CA for at least 6 months from
2008 through October 2016 (N ¼ 27) were included. The
diagnosis of persistent GD was made by a child psychologist and
a child psychiatrist and was based on the diagnostic criteria of the
Diagnostic and Statistical Manual of Mental Disorders, Fifth
Edition and the International Classiﬁcation of Diseases, Tenth
Revision.7 The decision to start medical treatment was made by
the multidisciplinary child gender team of Ghent University
Hospital (Ghent, Belgium).
Treatment consisted of CA (Androcur) 50 mg for at least 6
months in all participants followed by a combination of CA and
incremental doses of E (Progynova, Bayer AG; CA þ E) in a
subset (n ¼ 21) for at least 6 months. The others were too young
to be eligible for CSH therapy at the time of data analysis.
Criteria to start CSH therapy were based on the Endocrine So-
ciety guidelines.18 All adolescents were prescribed vitamin D
supplementation and a calcium-enriched diet during treatment.
Before the initiation of E, the adolescent and a legal guardian
were asked to sign an informed assent and consent, respectively,
to inform them that an off-label treatment was started, in
accordance with the recommendations of our institutional ethicalJ Sex Med 2017;14:747e757
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of Ghent University Hospital (Ghent, Belgium).Methods
Intake visits were aimed at excluding a disorder of sexual
development underlying GD and at determining the pubertal
(Tanner) stage by a physical examination performed by a pedi-
atric endocrinologist. CA (50 mg/d) was started in trans-girls
with Tanner stage G4 or higher in accordance with our local
treatment protocol (in earlier stages of puberty, GnRHas are
started). After at least 6 months, E was added if the adolescent
was at least 16 years old and had a persistent desire to proceed
with the gender change process. Follow-up visits were scheduled
every 6 months, and E doses were increased at every visit until a
maximum of 2 mg was reached (0.5 mg/d at start, 0.75 mg/
d after 6 months, 1 mg/d after 1 year, 1.5 mg/d after 18 months,
2 mg/d after 2 years). Psychological counseling was maintained
throughout treatment. Fertility issues were discussed thoroughly
throughout each treatment phase. Semen cryopreservation was
offered before the initiation of CA; adolescents can opt to delay
this procedure until an older age, requiring cessation of treatment
for at least 3 months. Alternatively, trans-girls can opt to cryo-
preserve testicular tissue at the time of orchidectomy.MAIN OUTCOME MEASURES
Anthropometrics, Physical Changes, and Side
Effect
At each visit, adolescents were asked which physical changes
and side effects they had experienced since the previous visit.
Breast development was scored according to Tanner stages by
physical examination performed by a pediatric endocrinologist.
Body weight (wearing only underwear) and height were
measured at each visit, and body mass index (BMI) was calcu-
lated. SD scores were calculated based on data provided by a
recent population-based study of adolescents of the same region
as our patients.25 Information on facial shaving frequency as
reported by the adolescent, breast tenderness, mood swings,
changes in appetite, fatigue, and the occurrence of hot ﬂushes
were systematically collected. Changes in body hair and sexual
arousability (ie, erections) were not systematically documented
unless reported by the adolescent.Biochemical and Hormone Parameters
Fasting blood sampling was performed at the start of CA and
CA þ E, and random blood sampling was done every 6 months.
Spectrophotometry (XE-5000, Sysmex, Kobe, Japan) was used to
measure hemoglobin (Hb) levels; DC impedance (XE-5000) was
used to measure hematocrit (Hct) levels; a rate-blanked Jaffé
kinetic assay (c701 [a þ b], Roche Diagnostics, Basel,
Switzerland) was used to measure creatinine; the UV-kinetic
(International Federation of Clinical Chemistry and Laboratory
Medicine) method without pyridoxal phosphate (Cobas c701,J Sex Med 2017;14:747e757Roche Diagnostics) was used to measure aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT); the enzymatic
colorimetric method (c701 [a þ b], Roche Diagnostics) was used
to measure triglycerides, total cholesterol, and high-density li-
poprotein cholesterol (HDL); an electro-chemoluminescence
assay (E170 Modular, Roche Diagnostics) was used to measure
free thyroxin, thyroid-stimulating hormone, luteinizing hormone
(LH), follicle-stimulating hormone, SHBG, estradiol (E2), and
dehydroepiandrosterone sulfate (DHEAS); liquid chromato-
graphic tandem mass spectrometry was used to measure testos-
terone; an immunoassay (Immulite, Siemens, Berlin, Germany)
was used to measure prolactin; and low-density lipoprotein
cholesterol (LDL) and free testosterone were calculated. The
interassay coefﬁcients of variation and serum limits of quantiﬁ-
cation, respectively, were 0.48% and 2 g/L for Hb, lower than
1.4% and 0.00 for Hct, 0.964% and 15 mmol/L for creatinine,
4.11% and 0.084 mkat/L for AST, 1.74% and 0.084 mkat/L for
ALT, 2.49% and 0.1 mmol/L for triglycerides, 1.3% and 0.1
mmol/L for total cholesterol, 3.33% and 0.078 mmol/L for
HDL, 7.4% and lower than 1.29 pmol/L for free thyroxin, 4.6%
and 0.02 mU/L for thyroid-stimulating hormone, 2.19% and
lower than 0.1 U/L for LH, 2.55% and 0.1 U/L for follicle-
stimulating hormone, 2.8% and 0.35 nmol/L for SHBG,
3.2% and 91.8 pmol/L for E2, 4.6% and lower than 0.0027
mmol/L for DHEAS, 6.5% and 0.347 nmol/L for testosterone,
and 7.4% and 21.7 pmol/L for prolactin.
The detection limits for LH, E2, and testosterone were not
reached in some cases at some time points. For values below
these limits, the limit was inputted for statistical analyses.Statistics
Statistical analysis was performed using IBM SPSS 24 (IBM
Corp, Armonk, NY, USA). A P value less than or equal to 0.05
was considered signiﬁcant. Statistical tests were aimed at
detecting changes of anthropometric, biochemical, and hormonal
parameters. Values at 6 and 12 months of treatment with CA
and CA þ E were compared with values before the start of the
respective medications. After testing for normality with the
Shapiro-Wilk test, the paired Student t-test or Wilcoxon signed-
ranks test was used as appropriate. A signiﬁcant result indicates a
signiﬁcant change after 6 or 12 months of treatment with CA or
CA þ E compared with before the start of the respective treat-
ment. The same statistic tests were performed to determine
whether the SD scores changed after 6 or 12 months of treat-
ment with CA or CA þ E. A signiﬁcant result indicates a
signiﬁcantly more or less pronounced weight, height, or BMI
gain compared with age-matched male peers based on cross-
sectional SD scores obtained from a recent large-scale (N >
15,500) population-based study.25 To assess whether changes in
prolactin levels or total testosterone levels were signiﬁcantly more
or less pronounced in adolescents with breast development, the
unpaired Student t-test or Mann-Whitney U-test was used after
testing for normality with the Shapiro-Wilk test.
Table 1. Summary of patient characteristics and side effects
Comorbidity Education Side effects CA CA þ E
Psychiatric* 6/27 (22.2%) ASO 4/27 (14.8%) Breast tenderness 2/27 (7.4%) 12/21 (57.1%)
Social† 6/27 (22.2%) TSO 8/27 (29.6%) Emotionality 3/27 (11.1%) 6/21 (28.6%)
DSD 0/27 (0%) BSO 10/27 (37.0%) Hunger 0/27 (0%) 5/21 (23.8%)
BUSO 1/27 (3.7%) Fatigue 10/27 (37%) 3/21 (14.3%)
KSO 4/27 (14.8%) Flushes 1/27 (3.7%) 3/21 (14.3%)
Smoking‡ Alcohol§ Side effects CA CA þ E
No 20/27 (74.1%) No 16/27 (59.3%) Decreased shaving need 15/27 (55.6%) 15/21 (71.4%)
Yes 7/27 (25.9%) Yes 11/27 (40.7%) Breast developmentk B2: 4/27 (14.8%) B3: 14/21 (66.7%)
High 2/27 (7.4%) High 3/27 (11.1%) B3: 4/27 (14.8%) B4: 2/21 (9.5%)
ASO ¼ theoretical education; BSO ¼ vocational training; BUSO ¼ school for children with learning difﬁculties; CA ¼ cyproterone acetate monotherapy;
CA þ E ¼ cyproterone acetate and 17b-estradiol combination therapy; DSD ¼ disorder of sexual development; KSO ¼ art school; TSO ¼ technical education.
*Psychiatric comorbidities diagnosed before diagnosis of gender dysphoria: autism spectrum disorder (n ¼ 3), depression (n ¼ 1), attention-deﬁcit/
hyperactivity disorder (n ¼ 1), and autism spectrum disorder and depression (n ¼ 1).
†Vulnerable social situation: single-parent family, foster care or institutionalized, or alcohol abuse by parent.
‡For smoking, “yes” indicates any amount of cigarettes on a regular basis and “high” indicates more than 20 cigarettes a day.
§For alcohol, “yes” indicates any amount and “high” indicates more than 21 consumptions a week.
kTanner stage.
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Patient and Treatment Characteristics
Data from 27 trans-girls who were treated with CA for at least
6 months were analyzed. One adolescent who interrupted CA
treatment because he no longer wanted to pursue sex reassign-
ment was excluded. At the time of data analysis, 21 adolescents
had been treated with CA þ E for at least 6 months and were
included in the analysis of CA þ E data. In some cases, owing to
the retrospective nature of the study and occasional sample loss,
not all parameters were available at each time point.
Data on educational level, comorbidities, and lifestyle char-
acteristics of the study population are presented in Table 1.
Mean age at start of CA and CA þ E was 16 years 6 months and
17 years 7 months, respectively. Mean treatment duration for CA
was 12 months and that for CA þ E was 16 months. Compared
with the general male Flemish population, a considerably larger
number of adolescents attended vocational training (mostly
hairdressing) or art school.Physical Changes and Side Effects
More than half the adolescents reported decreased facial
shaving frequency during CA, and an additional two underwent
laser treatment to remove facial hair. Although not systematically
assessed, some reported decreased spontaneous erections (data
not shown). Breast development (Tanner stages B2eB3) was
noticed during CA in 8 of 27 patients (29.6%). During CA þ E,
66.7% reached Tanner B3 and 9.5% reached Tanner B4, but
with objectively small and subjectively unsatisfactory breast
volume in most cases. Complaints of fatigue were prevalent
during CA, resolving in all but one adolescent after the addition
of estrogens. Breast tenderness, emotionality, and hunger were
frequently reported during CA þ E.Anthropometry
Mean height at start of CA and CA þ E was 174.6 and 175.6
cm, respectively. Growth was signiﬁcantly less compared with
age-matched peers, because all adolescents selected for this
treatment had already reached at least Tanner stage G4. No
clinically important changes in body weight and BMI were
observed throughout treatment. Compared with age-matched
male peers, based on SD scores,25 weight gain was signiﬁ-
cantly less during treatment with CA. However, after adjusting
for height (BMI), the difference was not signiﬁcant. Evolution
of weight, height, and BMI is presented in Table 2 and
Figure 1.Biochemical Analyses
Safety and Metabolic Parameters
The total number of missing values at each time point was 0 to
8, of which triglycerides and calculated LDL were most prone to
be missing (Tables 3 and 4, Figure 2).
Creatinine, Hb, and Hct levels slightly decreased during CA
and stabilized after the addition of E (Figure 2A). There were no
signiﬁcant changes in AST and ALT levels. A transient increase
of liver enzymes was seen in four adolescents. None of the pa-
tients reached the threshold of three times the upper reference
limit, which was considered the cutoff to stop treatment.
LDL levels did not change during the entire treatment period
(Figure 2B), whereas total cholesterol, HDL, and triglyceride
levels signiﬁcantly decreased during CA (P ¼ .019, .009, and
.016 respectively).
No signiﬁcant changes were noticed in any of the parameters
assessing insulin sensitivity (HbA1c, glucose levels, insulin levels,
or homeostasis model assessment index; data not shown).J Sex Med 2017;14:747e757
Table 2. Summary of anthropometric data
Treatment phase
Weight (kg) Height (cm) BMI (kg/m2)
Mean (SD) Mean (SD)* Mean (SD) Mean (SD)* Mean (SD) Mean (SD)*
CA6m 0.02 (6.07) 0.200 (0.427) þ0.5 (0.88) 0.138 (0.025) 0.15 (1.88) 0.128 (0.462)
P value† 0.989 0.039 0.017 <0.001 0.958 0.217
CA12m þ2.28 (7.20) 0.233 (0.531) þ1.2 (1.43) 0.309 (0.081) þ0.52 (2.18) 0.100 (0.602)
P value† 0.296 0.156 0.018 0.004 0.447 0.594
CA þ E0 þ1.21 (8.10) 0.311 (0.507) þ1.0 (1.55) 0.339 (0.101) þ0.19 (2.41) 0.172 (0.554)
P value† 0.525 0.016 0.013 0.004 0.663 0.205
CA þ E6m þ0.48 (3.12) 0.037 (0.299) þ0.3 (0.41) 0.050 (0.017) þ0.08 (1.03) 0.061 (0.331)
P value† 0.488 0.597 0.009 0.008 0.677 0.444
CA þ E12m þ2.41 (4.45) 0.008 (0.384) þ0.4 (0.58) 0.125 (0.025) þ0.66 (1.40) 0.042 (0.278)
P value† 0.054 0.944 0.020 <0.001 0.017 0.614
BMI ¼ body mass index; CA ¼ cyproterone acetate monotherapy; CA þ E ¼ cyproterone acetate and 17b-estradiol combination therapy; CA þ E0 ¼
difference during entire CA; CA þ E12m ¼ difference after 12 months of CA þ E (vs start of CA þ E); CA þ E6m ¼ difference after 6 months of CA þ E
(vs start of CA þ E); CA12m ¼ difference after 12 months of CA (vs start of CA); CA6m ¼ difference after 6 months of CA (vs start of CA).
*Compared with Flemish male peers.25
†Result of statistical tests.
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vant or caused clinical problems. None of the adolescents had a
venous thrombosis event during treatment.Hormone Levels
The total number of missing values at each time point was 0 to
7, and gonadotropins and testosterone showed the smallest
number of missing values (0 to 3).
Changes in thyroid-stimulating hormone and free thyroxin
levels were not considered clinically relevant (Tables 3 and
4). LH levels slightly increased and follicle-stimulating hor-
mone levels slightly decreased during CA. The levels of these
two hormones decreased after the addition of E but were
never suppressed (Figure 2E, F). E2 levels were mostly belowFigure 1. Panels A and B show box-and-whisker plots for the evolution o
represent 5 kg or 2 kg/m2. BMI ¼ body mass index; CA ¼ cyproterone a
combination therapy; CA þ E 0 ¼ weight or BMI evolution after entire C
(vs start of CAþ E); CAþ E 6m¼ weight or BMI evolution after 6 mont
after 12 months of CA (vs start of CA); CA 6m ¼ weight or BMI evoluti
J Sex Med 2017;14:747e757the detection limit of 91.8 pmol/L, even at 12 months of
CA þ E (corresponding to a dose of E 0.75 mg/d).
Therefore, we could not quantify the “real” change in E2
levels. Total and free testosterone levels signiﬁcantly and
progressively decreased during the course of treatment. Levels
decreased considerably below the male reference range but
did not reach the female-typical threshold (Figure 2C, D).
SHBG and DHEAS levels reached a nadir under CA and
were restored after the addition of E (Figure 2H). CA
resulted in a signiﬁcant increase of prolactin; none of the
adolescents developed clinical galactorrhea (Figure 2G).
Adolescents who experienced breast development during CA
did not show a greater increase in prolactin levels or a more
pronounced decrease in testosterone levels than adolescents
without breast development.f weight and BMI, respectively, during CA and CAþ E. Horizontal lines
cetate monotherapy; CA þ E ¼ cyproterone acetate and 17b-estradiol
A; CA þ E 12m ¼ weight or BMI evolution after 12 months of CA þ E
hs of CAþ E (vs start of CAþ E); CA 12m¼ weight or BMI evolution
on after 6 months of CA (vs start of CA).
Table 3. Summary of biochemical and hormonal data during CA monotherapy*
Test CA0, mean (SD) CA6m, mean (SD) P (CA0-6m) CA12m, mean (SD) P (CA0-12m)
Hemoglobin (g/L)† 150.0 (8.53) 139.2 (9.12) <.001 135.6 (7.89) .001
Hematocrit (proportion of 1.0)‡ 0.438 (0.019) 0.407 (0.022) <.001 0.399 (0.021) .002
Creatinine (mmol/L)§ 73.78 (13.16) 70.83 (9.56) .145 66.87 (10.83) <.001
Aspartate aminotransferase (mkat/L)k 0.34 (0.069) 0.31 (0.058) .175 0.32 (0.038) .677
Alanine aminotransferase (mkat/L){ 0.28 (0.126) 0.32 (0.151) .134 0.37 (0.131) .259
Triglycerides (mmol/L)# 0.873 (0.354) 0.764 (0.319) .333 0.742 (0.456) .028
Total cholesterol (mmol/L)** 3.816 (0.651) 3.688 (0.653) .349 3.569 (0.560) .173
High-density lipoprotein cholesterol (mmol/L)†† 1.292 (0.417) 1.174 (0.299) .118 1.049 (0.163) .068
Low-density lipoprotein cholesterol (mmol/L)‡‡ 2.123 (0.755) 2.086 (0.622) .766 2.279 (0.582) .749
Thyroid-stimulating hormone (mIU/L)§§ 2.23 (1.32) 2.16 (0.99) .546 2.12 (1.01) .678
Free thyroxin (pmol/L)kk 16.80 (2.23) 18.02 (2.08) .031 18.25 (3.19) .120
Luteinizing hormone (IU/L){{ 4.17 (2.05) 4.60 (2.04) .123 5.01 (1.89) .172
Follicle-stimulating hormone (IU/L)## 4.19 (2.53) 3.28 (2.12) .005 5.09 (4.04) .362
SHBG (nmol/L)*** 30.15 (10.52) 26.45 (8.84) .074 23.37 (10.35) .311
Estradiol (pmol/L)††† 114.9 (29.5) 91.8 (0) .005 91.8 (0) .109
Testosterone (nmol/L)‡‡‡ 15.82 (8.33) 8.61 (5.85) <.001 7.84 (6.34) .013
Free testosterone (pmol/L)§§§ 321.32 (148.8) 186.69 (102.9) .002 209.94 (182.7) .575
Prolactin (pmol/L)kkk 318.24 (138.22) 803.85 (300.04) <.001 760.81 (225.52) .003
DHEAS (mmol/L){{{ 7.94 (3.38) 7.91 (3.44) .954 6.91 (4.48) .012
CA ¼ cyproterone acetate monotherapy; CA0 ¼ before initiation of CA; CA12m ¼ after 12 months of CA; CA6m ¼ after 6 months of CA; DHEAS ¼
dehydroepiandrosterone sulfate; P (CA0-12m) ¼ P value for parameters at baseline vs after 12 months of CA; P (CA0-6m) ¼ P value for parameters at baseline
vs after 6 months of CA.
*Reference ranges can vary according to different stages of the menstrual cycle (maximum upper and lower limits of all cycle stages are represented).
Reference ranges also can vary according to different Tanner stages (maximum upper and lower limits of all Tanner stages are represented).
†Male reference ranges ¼ 130e160 for those < 18 years old, 129e173 for those > 18 years old; female reference ranges ¼ 120e160 for those < 18 years old,
118e148 for those > 18 years old.
‡Male reference ranges ¼ 0.37e0.49 for those < 18 years old, 0.39e0.497 for those > 18 years old; female reference ranges ¼ 0.36e0.46 for those < 18
years old, 0.358e0.437 for those > 18 years old.
§Reference ranges ¼ 46.852e69.836 for boys and girls 11e13 years old, 50.388e76.908 for boys and girls 13e15 years old, 63.648e103.428 for boys and
men > 15 years old, 48.62e84.864 for girls and women > 15 years old.
kMale reference ranges¼ 0e0.62; female reference range ¼ 0e0.52.
{Male reference ranges¼ 0.12e0.67; female reference range ¼ 0.12e0.52.
#Male reference ranges ¼ 0.362e1.413 for those 10e15 years old, 0.418e1.672 for those 15e20 years old; female reference ranges ¼ 0.418e1.48 for those
10e15 years old, 0.441e1.492 for those 15e20 years old.
**Male reference ranges ¼ 3.082e5.232 for those 10e15 years old, 2.927e5.102 for those 15e20 years old; female reference ranges ¼ 3.212e5.206 for
those 10e15 years old, 3.108e5.258 for those 15e20 years old.
††Male reference range ¼ 0.829e1.865; female reference range ¼ 1.010e2.486.
‡‡Male reference range ¼ 1.606e3.626 for those < 20 years old; female reference range ¼ 1.735e3.626 for those < 20 years old.
§§Male and female reference range ¼ 0.51e4.3 for those 11e20 years old.
kkMale and female reference range ¼ 12.613e20.978 for those 12e20 years old.
{{Male reference range ¼ 1e9; female reference range ¼ 1e96 (cycle dependent).
##Male reference range ¼ 1e12; female reference range ¼ 2e22 (cycle dependent).
***Male reference range ¼ 11.6e71.2 for those < 70 years old; female reference range ¼ 10.5e163.7 for those < 50 years old.
†††Male reference range ¼ 99.484e191.626; female reference range ¼ 98.016e1,152.694 (cycle dependent).
‡‡‡Male reference range ¼ 11.139e34.874; female reference range ¼ 0.291e1.669 for those < 50 years old.
§§§Male reference range ¼ 208.2e867.5; female reference range ¼ 0.694e22.208.
kkkMale reference range ¼ 173.9e739.1; female reference range ¼ 260.9e695.6.
{{{Male reference range ¼ 1.89e13.28; female reference range ¼ 1.76e9.94.
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Most centers use GnRHas to suppress endogenous gonadal
hormones in transgender adolescents.26 However, GnRHas are
expensive, not reimbursed in Belgium as in many other coun-
tries, and do not reverse secondary sexual characteristics in late-
pubertal adolescents or induce changes toward the desired sex.
For these reasons, the antiandrogenic progestin CA is mostlyused in trans-girls presenting beyond Tanner stage 3 at our
pediatric gender clinic. However, no data exist on the efﬁcacy
and safety of CA as monotherapy or in combination with CSHs
in adolescent trans-girls.
Our results suggest that administration of CA for 6 to 12
months, although not resulting in suppression of gonadotropins,
has important clinical effects, because it effectively decreasedJ Sex Med 2017;14:747e757
Table 4. Summary of biochemical and hormonal data during CA þ E therapy*
Test
CA þ E0,
mean (SD)
CA þ E6m,
mean (SD) P (CA þ E0-6m)
CA þ E12m,
mean (SD) P (CA þ E0-12m)
Hemoglobin (g/L)† 138.1 (9.05) 138.1 (8.03) .970 137.6 (8.91) .861
Hematocrit (proportion of 1.0)‡ 0.403 (0.021) 0.398 (0.021) .257 0.401 (0.019) .530
Creatinine (mmol/L)§ 69.71 (10.04) 70.76 (13.99) .708 71.25 (8.93) .002
Aspartate aminotransferase (mkat/L)k 0.32 (0.080) 0.31 (0.103) .218 0.29 (0.038) .502
Alanine aminotransferase (mkat/L){ 0.36 (0.213) 0.37 (0.305) .616 0.33 (0.107) .294
Triglycerides (mmol/L)# 0.633 (0.117) 0.929 (0.427) .179 0.821 (0.329) .345
Total cholesterol (mmol/L)** 3.716 (0.682) 3.781 (0.632) .571 3.515 (0.889) .797
High-density lipoprotein cholesterol
(mmol/L)††
1.205 (0.306) 1.225 (0.296) .597 1.269 (0.240) .086
Low-density lipoprotein cholesterol
(mmol/L)‡‡
1.851 (0.431) 1.741 (0.505) .571 2.272 (0.495) .639
Thyroid-stimulating hormone (mIU/L)§§ 2.42 (0.96) 1.95 (0.88) .018 2.02 (1.10) .480
Free thyroxin (pmol/L)kk 18.28 (2.39) 18.53 (2.47) .663 18.79 (2.03) .607
Luteinizing hormone (IU/L){{ 5.54 (2.28) 4.27 (2.60) .035 3.15 (2.99) .031
Follicle-stimulating hormone (IU/L)## 5.19 (3.51) 4.27 (3.31) .135 2.78 (3.04) .057
SHBG (nmol/L)*** 28.53 (9.45) 34.22 (12.69) .029 42.02 (16.80) .034
Estradiol (pmol/L)††† 91.8 (0) 118.6 (55.2) .008 121.1 (58.5) .043
Testosterone (nmol/L)‡‡‡ 9.58 (6.45) 6.16 (5.22) .003 5.82 (8.61) .035
Free testosterone (pmol/L)§§§ 173.15 (115.7) 89.87 (71.1) .004 70.44 (70.7) .013
Prolactin (pmol/L)kkk 727.34 (323.78) 648.21 (286.22) .586 460.40 (229.69) .011
DHEAS (mmol/L){{{ 7.27 (3.19) 8.17 (3.57) .166 7.37 (3.19) .166
CA þ E ¼ cyproterone acetate and 17b-estradiol combination therapy; CA þ E0: before initiation of CA þ E; CA þ E12m ¼ after 12 months of CA þ E;
CA þ E6m ¼ after 6 months of CA þ E; DHEAS ¼ dehydroepiandrosterone sulfate; P (CA þ E0-12m) ¼ P value for parameters at baseline vs after 12 months
of CA þ E; P (CA þ E0-6m) ¼ P value for parameters at baseline vs after 6 months of CA þ E.
*Reference ranges can vary according to different stages of the menstrual cycle (maximum upper and lower limits of all cycle stages are represented).
Reference ranges also can vary according to different Tanner stages (maximum upper and lower limits of all Tanner stages are represented).
†Male reference ranges ¼ 130e160 for those < 18 years old, 129e173 for those > 18 years old; female reference ranges ¼ 120e160 for those < 18 years old,
118e148 for those > 18 years old.
‡Male reference ranges ¼ 0.37e0.49 for those < 18 years old, 0.39e0.497 for those > 18 years old; female reference ranges ¼ 0.36e0.46 for those < 18
years old, 0.358e0.437 for those > 18 years old.
§Reference ranges ¼ 46.852e69.836 for boys and girls 11e13 years old, 50.388e76.908 for boys and girls 13e15 years old, 63.648e103.428 for boys and
men > 15 years old, 48.62e84.864 for girls and women > 15 years old.
kMale reference range ¼ 0e0.62; female reference range ¼ 0e0.52.
{Male reference ranges¼ 0.12e0.67; female reference range ¼ 0.12e0.52.
#Male reference ranges ¼ 0.362e1.413 for those 10e15 years old, 0.418e1.672 for those 15e20 years old; female reference ranges ¼ 0.418e1.48 for those
10e15 years old, 0.441e1.492 for those 15e20 years old.
**Male reference ranges ¼ 3.082e5.232 for those 10e15 years old, 2.927e5.102 for those 15e20 years old; female reference ranges ¼ 3.212e5.206 for
those 10e15 years old, 3.108e5.258 for those 15e20 years old.
††Male reference range ¼ 0.829e1.865; female reference range ¼ 1.010e2.486.
‡‡Male reference range ¼ 1.606e3.626 for those < 20 years old; female reference range ¼ 1.735e3.626 for those < 20 years old.
§§Male and female reference range ¼ 0.51e4.3 for those 11e20 years old.
kkMale and female reference range ¼ 12.613e20.978 for those 12e20 years old.
{{Male reference range ¼ 1e9; female reference range ¼ 1e96 (cycle dependent).
##Male reference range ¼ 1e12; female reference range ¼ 2e22 (cycle dependent).
***Male reference range ¼ 11.6e71.2 for those < 70 years old; female reference range ¼ 10.5e163.7 for those < 50 years old.
†††Male reference range ¼ 99.484e191.626; female reference range ¼ 98.016e1,152.694 (cycle dependent).
‡‡‡Male reference range ¼ 11.139e34.874; female reference range ¼ 0.291e1.669 for those < 50 years old.
§§§Male reference range ¼ 208.2e867.5; female reference range ¼ 0.694e22.208.
kkkMale reference range ¼ 173.9e739.1; female reference range ¼ 260.9e695.6.
{{{Male reference range ¼ 1.89e13.28; female reference range ¼ 1.76e9.94.
Cyproterone Acetate and Estradiol for Late-Pubertal Trans-Girls 753facial hair growth in most adolescents and induced breast
development in one third of trans-girls. Most adolescents rated
the effects of CA as very positive. After the addition of E (0.5 mg
was increased to 0.75 mg after 6 months), 66.7% and 9.5% of
trans-girls reached Tanner stage B3 and B4, respectively, withinJ Sex Med 2017;14:747e75712 months of treatment. Based on circumstantial evidence in
adult transwomen, it has been hypothesized that breast growth
might be more pronounced when CSH treatment is started
earlier.24,27 This could not be conﬁrmed in our study, because
the obtained breast volume was limited in many trans-girls, or at
Figure 2. Box-and-whisker plots of biochemical parameters. Large asterisks symbolize signiﬁcant changes compared with baseline. Gray
zones represent the female reference range and hatched zones represent the male reference range for (A) hemoglobin (g/dL; multiply by 10
for SI units [g/L]), (B) low-density lipoprotein cholesterol (mg/dL; multiply by 0.0259 for SI units [mmol/L]), (C) testosterone (ng/dL;
multiply by 0.0347 for SI units [nmol/L]), (D) free testosterone (ng/dL; multiply by 34.7 for SI units [pmol/L]), (E) luteinizing hormone (U/L),
(F) follicle-stimulating hormone (U/L), (G) prolactin (mg/L; multiply by 43.478 for SI units [pmol/L]), and (H) SHBG (nmol/L).
CA ¼ cyproterone acetate monotherapy; CA þ E ¼ cyproterone acetate and 17b-estradiol combination therapy; CA þ E 0 ¼ before start of
CA þ E; CA þ E 12m ¼ after 12 months of CA þ E; CA þ E 6m ¼ after 6 months of CA þ E; CA 0 ¼ baseline values; CA 12m ¼ after 12
months of CA; CA 6m ¼ after 6 months of CA.
J Sex Med 2017;14:747e757
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Cyproterone Acetate and Estradiol for Late-Pubertal Trans-Girls 755best moderate in some, and most trans-girls expressed a desire for
later breast augmentation surgery. This is similar to results in
adult transwomen.24 Retrospectively, because that no detectable
E2 levels were reached in most adolescents, initial E2 doses
might have been too low to result in optimal breast development,
and our protocol has been adjusted accordingly. Complaints of
hypogonadism, especially fatigue, were relatively frequent during
CA, whereas increased hunger, emotionality, and tenderness of
nipples and breasts were often reported by adolescents taking
CA þ E.
Androgen deprivation therapy in adult men has been associ-
ated with weight and BMI gain and a decrease in lean body
mass.28,29 Similarly, in transgender adults, CA þ E increases
weight and body fat.10,30 Such changes were not observed in this
study. Older individuals could be more vulnerable to hormone-
induced weight changes. Alternatively, because people with GD
are more prone to body dissatisfaction,31 we cannot exclude that
the status quo in BMI resulted from changes in diet and physical
exercise of the adolescents to prevent weight gain and conform
more to female ideals, as suggested previously.32
No serious adverse events occurred throughout the studied
period, and typical safety parameters such as creatinine and liver
function tests did not show clinically relevant changes. Transient
ALT and AST increases were observed sporadically, in line with
other reports,10,33 but never required interruption of treatment.
High doses of CA, as used in androgen deprivation therapy, have
been associated with severe liver dysfunction.34 Therefore, we
consider periodic monitoring of liver function during treatment
important.
Sex steroids underlie differences in Hb and Hct levels between
men and women. Estrogens cause vasodilation, whereas andro-
gens cause vasoconstriction of the microvasculature in the kid-
ney. In men, circulating androgens lead to lower Hct levels in the
juxtaglomerular apparatus through the Fahraeus effect, leading to
erythropoietin production at higher Hct levels when measured in
peripheral veins than in women.35,36 Accordingly, when using
CA alone, Hb and Hct levels progressively changed to female
reference ranges through androgen deprivation.
Importantly, treatment did not alter the cardiovascular and
metabolic risk proﬁle of our adolescent population. In adults,
CA þ E has been shown to increase fasting insulin levels and
decrease insulin sensitivity.37 In addition, some37,38 but not all39
adult studies have reported the development of a more favorable
“feminine” lipid proﬁle using CA þ E, with higher total
cholesterol and HDL levels and lower LDL levels. The absence of
signiﬁcant alterations in lipid proﬁles in our study might be due
to the young age of the participants, because hypercholesterole-
mia does not commonly develop before early adulthood.40
CA decreased adrenal androgen production, represented by
lower DHEAS values. Of note, CA has been reported to suppress
adrenal function, including glucocorticoid biosynthesis, and to
result in lower adrenal weight.41,42 Clinical signs of acute adrenalJ Sex Med 2017;14:747e757insufﬁciency were not observed in our population, but because
adrenocorticotropic hormone and cortisol levels were not
measured, we cannot exclude that the frequently encountered
complaints of fatigue might have resulted (in part) from chronic
adrenal insufﬁciency. Further studies will need to address this
critical issue.
CA was effective in decreasing total and free testosterone
levels, although the upper female-typical threshold was not
reached. Moreover, gonadotropin levels were only slightly
inﬂuenced by CA but decreased during CA þ E, which is similar
to other studies in adults.43,44 E2 levels increased in some pa-
tients after the addition of E but in many adolescents remained
below the detection limit, especially with the lowest E dose of 0.5
mg. More sensitive detection methods such as liquid chro-
matographic tandem mass spectrometry are necessary to docu-
ment these subtle changes. However, because no side effects were
observed while introducing E and because breast development
was considered poor in the ﬁrst 12 months after the addition of
E, we recommend faster dose increments or a higher starting
than those applied in this study. Accordingly, the schedule of E
introduction in our center has been changed to 0.5 mg/d at the
start, 1 mg/d after 6 months, and 2 mg/d after 1 year. Whether
this results in more satisfactory breast development and/or full
gonadotropin suppression remains to be determined.
This study is, to our knowledge, the ﬁrst report on the use of
CA in adolescent trans-girls and one of the few studies reporting
on CSH treatment in this population. However, it has the typical
limitations of a retrospective analysis: some data were missing,
causal relations cannot be established, and reported side effects
are limited to those recorded in the patients’ ﬁles and therefore
can be an underestimation. Although gonadotropins were not
suppressed with CA, subjectively, adolescents experienced clear
beneﬁcial effects resulting from decreased testosterone activity.
Larger prospective studies comparing the clinical effects and
psychological well-being of trans-girls using GnRHa vs CA are
needed to determine the role of these respective medications in
late-pubertal transgender adolescents while they are awaiting
eligibility for CSH treatment. Likewise, a prospective compari-
son of different E dosing regimens for induction of desired sexual
characteristics is needed.CONCLUSION
Although CA did not fully suppress androgen levels, it effec-
tively and safely decreased some of the effects of endogenous
androgens. As with GnRHa, established secondary sexual char-
acteristics did not regress. However, while using CA, subtle
changes toward the desired sex took place, such as limited breast
development and a shift in some biochemical parameters.
Although direct comparative studies need to be performed ﬁrst,
we suggest that, if conﬁrmed, CA could offer a safe and valuable
alternative for GnRHa. Especially adolescents who have
advanced pubertal development at the time they are eligible for
756 Tack et almedical treatment and in a setting where the costs of GnRHa are
not reimbursed could beneﬁt from this treatment.Corresponding Author: Martine Cools, MD, PhD, Princess
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